DCAT Research & Benchmarking

DCAT Research & Benchmarking

DCAT’s 2022 Study: Incorporating Sustainability in the Bio/Pharmaceutical Supply Chain

DCAT’s Research & Benchmarking Committee fielded a survey in late 2021/early 2022 to examine the driving factors surrounding sustainability and the progress being made toward sustainability in the supply chain (including manufacturing, packaging, and logistics) of the bio/pharma industry.

DCAT Member Companies can now access the final complimentary report as a value-added member benefit.

The report examines:

  • Sustainability goals for Bio/Pharma companies and suppliers.
  • Company objectives.
  • Measurable targets for Bio/Pharma companies and suppliers.
  • Timelines to complete sustainability goals/objectives.

The study answers these all-important questions:

  • Have Bio/Pharma companies articulated clear sustainability goals for themselves? For their suppliers? If so, what are the main objectives?
  • Have Bio/Pharma companies set specific, measurable targets for their supply chain and suppliers? If so, how are they measuring them?
  • Are Bio/Pharma companies requiring their suppliers to meet those targets or just encouraging them to do so? How much time have suppliers been given to meet the targets?
  • Have sustainability objectives and targets been integrated into supplier qualification processes? Supplier performance reviews? Regular supplier meetings?

DCAT Member Company employees can download a complimentary copy of the report here.

About DCAT Research & Benchmarking

DCAT Research & Benchmarking is a complimentary, value-added member benefit providing in-depth studies that examine the crucial issues impacting the bio/pharmaceutical manufacturing value chain and the bio/pharma customer—supplier relationship. DCAT Research & Benchmarking studies are developed by the DCAT Research & Benchmarking Committee, composed of member representatives with diverse industry experience, to identify the topics of greatest interest for DCAT member companies and is administered and prepared using an external research firm.

DCAT Research & Benchmarking Report Archives

To access the reports, contact Miriam O’Donnell at modonnell@dcat.org or 856.388.2972. 

Managing Business Continuity Risks

Details how Bio/pharmaceutical companies and suppliers are managing business continuity risks resulting from the COVID-19 pandemic and how lessons learned are affecting their approach to supply-risk management overall. (2020)

Managing Bio/Pharma Supply Chains in an Uncertain Global Trade Environment

Provides insights on whether bio/pharma companies and their suppliers believe the deteriorating trade environment is a major threat, and what they are doing to confront the real and potential risks to their supply chains. (2019)

Examining the Current and Future Alignment of the Pharma Customer—Supplier Relationship

Evaluates the current and near-future imperatives for both pharma customers and suppliers, highlighting areas of alignment and misalignment and the opportunities for improvement. (2018)

Value-Based Metrics: Examining the Pharma Customer—Supplier Relationship

Examines the practices and key metrics used by both pharma companies and suppliers to measure the benefits of value-creation activities in the supply of direct materials. (2017)

Value Creation in Pharmaceutical Procurement

Surveying the CPOs of large to mid-sized pharma companies, the study examines Procurement’s role internally and with suppliers to deliver value for achieving corporate and business goals. (2016)